Form 8-K PLIANT THERAPEUTICS, For: May 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital
May 7, 2024 6:19 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $54.00) while maintaining a Outperform rating.
The analyst comments "PLRX's IPF program remains on track with the ph.IIb expected to complete enrollment 1Q25. While this likely... More
Pliant Therapeutics (PLRX) PT Lowered to $44 at Citi
May 7, 2024 5:46 AM EDTCiti analyst David Lebowitz lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $44.00 (from $45.00) while maintaining a Buy rating.
The analyst comments "Pliant reported 1Q24 financial results and provided an update on the status of its pipeline programs. Over the... More
